<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03377283</url>
  </required_header>
  <id_info>
    <org_study_id>UN4640</org_study_id>
    <nct_id>NCT03377283</nct_id>
  </id_info>
  <brief_title>Peri-operative rATG-perfusion of Solid Transplants</brief_title>
  <acronym>ATG-perfusion</acronym>
  <official_title>Reduction of Ischemic-reperfusion Injury by Ex-vivo ATG-perfusion of Kidneys and Livers Prior Organ Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University Innsbruck</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University Innsbruck</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The increasing demand for organ transplantation and the shortage of available organs limit
      the success of organ transplantation programs. Consequently, acceptance of expanded criteria
      donor (ECD) organs with the consequences of higher risk of unfavorable transplantation
      outcome has become an increasing reality. Among the most prominent characteristics
      distinguishing ECD from Standard Criteria Donors (SCD) are risk factors including brain death
      (BD) or prolonged cold ischemia time (CI) amplifying ischemia reperfusion injury (IRI).
      Currently there are no standard regimens to improve the quality of ECD organs. Therefore,
      donor organ treatment might be a promising approach to substantially improve organ quality.
      It will be investigated whether the application of the peri-operative perfusion of kidneys
      and livers with the polyclonal antibody rabbit antithymocyte globulin (rATG) ameliorates IRI.

      This trial is designed as a parallel armed randomized controlled trial.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 17, 2012</start_date>
  <completion_date type="Actual">February 24, 2016</completion_date>
  <primary_completion_date type="Actual">March 4, 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Graft function</measure>
    <time_frame>Day 7</time_frame>
    <description>Graft function from baseline defined as serum creatinine (KTx arm) and aspartate transaminase (LTx arm).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Graft function - creatinine</measure>
    <time_frame>Days 1-7 post transplantation, month 3, month 6, month 12</time_frame>
    <description>Graft function from baseline defined as serum creatinine (mg/dL) for the KTx arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft function - glomeralur filtration rate</measure>
    <time_frame>Days 1-7 post transplantation, month 3, month 6, month 12</time_frame>
    <description>Graft function from baseline defined as glomerular filtration rate (ml/min/1.73M2) for the KTx arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft function - serum urea</measure>
    <time_frame>Days 1-7 post transplantation, month 3, month 6, month 12</time_frame>
    <description>Graft function from baseline defined as serum urea (mg/dL) for the KTx arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft function - aspartate transaminase</measure>
    <time_frame>Days 1-7 post transplantation, month 3, month 6, month 12</time_frame>
    <description>Graft function from baseline defined as aspartate transaminase (mg/dL) for LTx arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft function - alanine transaminase</measure>
    <time_frame>Days 1-7 post transplantation, month 3, month 6, month 12</time_frame>
    <description>Graft function from baseline defined as alanine transaminase (mg/dL) for LTx arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft function - total serum bilirubin</measure>
    <time_frame>Days 1-7 post transplantation, month 3, month 6, month 12</time_frame>
    <description>Graft function from baseline defined as total serum bilirubin (mg/dL) for LTx arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft function - gamma-glutamyl transpeptidase</measure>
    <time_frame>Days 1-7 post transplantation, month 3, month 6, month 12</time_frame>
    <description>Graft function from baseline defined as gamma-glutamyl transpeptidase (mg/dL) for LTx arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft function - alkaline phosphatase</measure>
    <time_frame>Days 1-7 post transplantation, month 3, month 6, month 12</time_frame>
    <description>Graft function from baseline defined as alkaline phosphatase (mg/dL) for LTx arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft function - quick value</measure>
    <time_frame>Days 1-7 post transplantation, month 3, month 6, month 12</time_frame>
    <description>Graft function from baseline defined as quick value (%) for LTx arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient age - recipient</measure>
    <time_frame>Day zero, at the time point of transplantation</time_frame>
    <description>Recipient age (years).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient age - donor</measure>
    <time_frame>Day zero, at the time point of transplantation</time_frame>
    <description>Donor age (years).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI - recipient</measure>
    <time_frame>Day zero, at the time point of transplantation</time_frame>
    <description>Recipient BMI (weight (lb) / [height (in)]2 x 703).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI - donor</measure>
    <time_frame>Day zero, at the time point of transplantation</time_frame>
    <description>Donor BMI (weight (lb) / [height (in)]2 x 703).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sex - recipient</measure>
    <time_frame>Day zero, at the time point of transplantation</time_frame>
    <description>Recipient sex.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sex - donor</measure>
    <time_frame>Day zero, at the time point of transplantation</time_frame>
    <description>Donor sex.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cold ischemia time</measure>
    <time_frame>during transplantation</time_frame>
    <description>Cold ischemia time (hours) from cross-clamping until start of anastomosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Warm ischemia time</measure>
    <time_frame>during transplantation</time_frame>
    <description>Warm ischemia time (hours) is the time from start of anastomosis until reperfusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Panel-reactive antibodies</measure>
    <time_frame>Day zero, at the time point of transplantation</time_frame>
    <description>Presence of panel-reactive antibodies (%) in KTx recipients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital stay</measure>
    <time_frame>after transplantation</time_frame>
    <description>Hospital stay (days) after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU stay</measure>
    <time_frame>after transplantation</time_frame>
    <description>Intensive care unit stay (days) after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>up to 12 month</time_frame>
    <description>Death rate in the investigated groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft loss</measure>
    <time_frame>up to 12 month</time_frame>
    <description>Graft loss rate in the investigated groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HLA missmatch</measure>
    <time_frame>Day zero, at the time point of transplantation</time_frame>
    <description>Human leukocyte antigen mismatches in KTx recipients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delayed graft function</measure>
    <time_frame>after transplantation</time_frame>
    <description>Development of delayed graft function (requirement of dialysis within the first 7 post operative days) in KTx recipients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Experimental analysis of perioperative taken biopsies</measure>
    <time_frame>Peri-operatively (zero hour biopsy)</time_frame>
    <description>mRNA Expression of pro-inflammatory and anti-inflammatory cytokine/chemokine pattern in biopsies will be analysed to evaluate immunactivation of the organ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Experimental analysis of peripheral blood monunuclear cells</measure>
    <time_frame>prior transplantation, days 1-7 post transplantation, month 3, month 6, month 12 for lymphocyte expression analysis of peripheral blood</time_frame>
    <description>Leukocyte-composition and activation pattern will be analysed from peripheral blood via flow cytometry of the recipient and the donor</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Organ Preservation Solutions</condition>
  <arm_group>
    <arm_group_label>AP-KTx/LTx</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transplant recipients receiving an rATG-perfused kidney or liver</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CP-KTx/LTx</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Transplant recipients receiving a control-perfused kidney or liver.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>organ perfusion with rabbit anti-thymocyte globulin (rATG)</intervention_name>
    <arm_group_label>AP-KTx/LTx</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>organ perfusion with saline</intervention_name>
    <arm_group_label>CP-KTx/LTx</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients receiving a kidney or liver transplant from deceased donors

        Exclusion Criteria:

          -  Hepatitis C Virus/Human Immunodeficiency Virus, undergoing re-transplantation or under
             a public guardian
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2017</study_first_submitted>
  <study_first_submitted_qc>December 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2017</study_first_posted>
  <last_update_submitted>December 20, 2017</last_update_submitted>
  <last_update_submitted_qc>December 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University Innsbruck</investigator_affiliation>
    <investigator_full_name>Katja Kotsch</investigator_full_name>
    <investigator_title>Univ. Prof. Dr. Katja Kotsch</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

